News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
BioCurex Inc. Signs Consent to Transfer Abbott Laboratories’s RECAF Licensing Agreement to General Electric Company
July 2, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
RICHMOND, British Columbia, July 2, 2007 (PRIME NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) announced today that, upon request from Abbott Labs, the Company has signed a document transferring Abbott's RECAF licensing agreement to General Electric (GE).
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Abbott Laboratories
MORE ON THIS TOPIC
IPO
2026 IPO stock tracker: How newly public biotechs are performing
August 26, 2026
·
1 min read
·
Gabrielle Masson
FDA
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
August 26, 2026
·
2 min read
·
Jef Akst
Layoff Tracker
Cellares cuts jobs after losing pharma customer
August 25, 2026
·
86 min read
·
BioSpace Editorial Staff
Deals
China’s Haisco forms immunology biotech with up to $1.5B from American VCs
August 25, 2026
·
1 min read
·
Annalee Armstrong